Background: Amyloid PET allows for the assessment of amyloid β status in the brain, distinguishing true Alzheimer’s disease from Alzheimer’s disease-mimicking conditions. Around 15-20% of patients with clinically probable Alzheimer’s disease have been found to have no significant Alzheimer’s pathology on amyloid PET. However, a limited number of studies had been conducted on this subpopulation in terms of clinical progression.

Objective: We investigated the risk factors that could affect the progression to dementia in patients with amyloid-negative amnestic mild cognitive impairment (MCI).

中文翻译：

---

阐明从淀粉样蛋白阴性的遗忘性轻度认知障碍发展为痴呆症的危险因素

背景：淀粉样蛋白 PET 允许评估大脑中的淀粉样蛋白 β 状态，将真正的阿尔茨海默病与阿尔茨海默病模拟病症区分开来。大约 15-20% 的临床上可能患有阿尔茨海默病的患者在淀粉样蛋白 PET 上被发现没有明显的阿尔茨海默病病理。然而，就临床进展而言，对该亚群进行的研究数量有限。

目的：我们调查了可能影响淀粉样蛋白阴性遗忘性轻度认知障碍 (MCI) 患者进展为痴呆的风险因素。